Expand all sections

Forigerimod (Rigerimod)

Lupuzor

Extended indication Systemic Lupus erythematosus (SLE).
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Forigerimod (Rigerimod)
Domain Chronic immune diseases
Main indication Other chronic immune diseases
Extended indication Systemic Lupus erythematosus (SLE).
Proprietary name Lupuzor
Manufacturer ImmuPharma
Route of administration Subcutaneous
Therapeutical formulation Injection

Registration

Registration route Centralised (EMA)
Particularity New medicine
Expected Registration 2019
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

Patient volume

< 357

Market share is generally not included unless otherwise stated.
Additional remarks Een paar duizend patienten. In de beoordeling van Belimumab heeft het zorginstituut gerekend met: 'De prevalentie van SLE is 28-40 per 100,000 inwoners (~4.470 patiënten in Nederland). Ongeveer 8% van de patiënten met SLE heeft een hoge mate van ziekteactiviteit, ondanks een standaardbehandeling (zo’n 357 patiënten).'

Expected cost per patient per year

References Prescribing outlook 2017
Additional remarks Waarschijnlijk hoge kosten

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.